{
    "clinical_study": {
        "@rank": "62074", 
        "arm_group": [
            {
                "arm_group_label": "Conventional Treatment plus DLE", 
                "arm_group_type": "Experimental", 
                "description": "Conventional treatment plus DLE\nConventional treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend;\nDialyzed Leukocyte Extracts as Adjuvant Treatment:  oral DLE (Transferon) (2mg/5mL), then every day for 5 days, and then every 72hrs to complete one month."
            }, 
            {
                "arm_group_label": "Conventional treatment plus placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Conventional treatment plus placebo:\noral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days,  then every 48h for 10 days and suspend; plus oral placebo, every day for 5 days, then every 72hrs to complete one month."
            }
        ], 
        "brief_summary": {
            "textblock": "Patients with atopic dermatitis treated with conventional treatment plus Dialyzed Leukocyte\n      Extracts (DLE-oral Transferon) as adjuvant,  have better clinical outcome than patients\n      treated only with conventional treatment."
        }, 
        "brief_title": "Efficacy Study of Dialyzed Leukocytes Extracts to Treat Paediatric Moderate Atopic Dermatitis", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Childhood Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Atopic dermatitis diagnosis by Hanifin and Rajka classification\n\n          -  Dermatitis severity: Moderate, according with SCORAD index.\n\n          -  Patients without treatment of topical steroids or immunosuppressants in the last 3\n             weeks.\n\n          -  Patients with \"informed consent form\" signed by both parents, or advisor.\n\n          -  Patients 7 years old or older whom have signed the assent form\n\n        Exclusion Criteria:\n\n          -  Patient who were treated with topical, or systemic steroids  and/or\n             immunosuppressants and they cannot discontinue their treatment.\n\n          -  Patients who lived far from the hospital and they could not go to the visits."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01902836", 
            "org_study_id": "IC-11-06"
        }, 
        "intervention": [
            {
                "arm_group_label": "Conventional Treatment plus DLE", 
                "description": "Paediatric patients with diagnosis of atopic dermatitis according to Hanifin and Rajka and evaluated with SCORAD as moderate atopic dermatitis were included. Patients were randomized and received in a double blind placebo-controlled treatment:\nGroup 1: Conventional treatment plus DLE Conventional Treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; plus oral DLE (Transferon) (2mg/5mL), every day for 5 days, then every 72hrs to complete one month", 
                "intervention_name": "Conventional treatment plus DLE", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Transferon", 
                    "Dialyzable Leukocytes Extracts"
                ]
            }, 
            {
                "arm_group_label": "Conventional treatment plus placebo", 
                "description": "Group 2: Conventional treatment plus placebo. Conventional treatment: Cetirizine 0.25mg/kg oral, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; and oral placebo, every day for 5 days, then every 72hrs to complete one month.", 
                "intervention_name": "Conventional treatment plus placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chlorpheniramine", 
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Dialyzable Leukocyte Extracts", 
            "Transferon", 
            "atopic dermatitis"
        ], 
        "lastchanged_date": "July 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "M\u00e9xico", 
                    "country": "Mexico", 
                    "state": "DF", 
                    "zip": "06720"
                }, 
                "name": "Hospital Infantil de M\u00e9xico, Fed\u00e9rico G\u00f3mez"
            }
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Human Dialyzed Leukocytes Extracts in Paediatrics Patients With Moderate Atopic Dermatitis.", 
        "overall_official": {
            "affiliation": "Hospital Infantil de M\u00e9xico Federico G\u00f3mez", 
            "last_name": "Mirna Toledo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Mexico: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To determine clinical outcome by SCORAD.", 
            "measure": "Clinical outcome evaluated by SCORAD", 
            "safety_issue": "No", 
            "time_frame": "Day 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01902836"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Instituto de Oftalmolog\u00eda Fundaci\u00f3n Conde de Valenciana", 
            "investigator_full_name": "Maria C Jimenez Martinez", 
            "investigator_title": "PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To evaluate immunophenotypical changes, on peripheral blood mononuclear cells (PBMC) before, at day 14, and end of treatment.\nImmunophenotypical changes in this study are defined as changes in CLA and CD103 expression on PBMC; and changes in frequency of CD4+CD25+FOXP3 regulatory T cells, before, at day 14, and at end of treatment.", 
            "measure": "Immunophenotypical changes induced by adjuvant treatment (DLE) (oral Transferon)", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "source": "National Polytechnic Institute, Mexico", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Hospital Infantil de Mexico Federico Gomez", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Instituto de Oftalmolog\u00eda Fundaci\u00f3n Conde de Valenciana", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Polytechnic Institute, Mexico", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}